Novel CD20 monoclonal antibodies for lymphoma therapy (original) (raw)
References
Coiffier B: Rituximab in the treatment of diffuse large B-cell lymphomas. Semin Oncol. 2002, 29 (1 Suppl 2): 30-35. ArticleCASPubMed Google Scholar
Coiffier B: Rituximab in diffuse large B-cell lymphoma. Clin Adv Hematol Oncol. 2004, 2 (3): 156-157. PubMed Google Scholar
Coiffier B: Rituximab and CHOP-like chemotherapy in good-prognosis diffuse large-B-cell lymphoma. Nature clinical practice Oncology. 2006, 3 (11): 594-595. ArticleCASPubMed Google Scholar
Coiffier B: Rituximab therapy in malignant lymphoma. Oncogene. 2007, 26 (25): 3603-3613. 10.1038/sj.onc.1210376. ArticleCASPubMed Google Scholar
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002, 346 (4): 235-242. 10.1056/NEJMoa011795. ArticleCASPubMed Google Scholar
Mishima Y, Terui Y, Yokoyama M, Nishimura N, Sakajiri S, Ueda K, Kuboki Y, Nakano K, Suzuki K, Nara E: R-CHOP with dose-attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphoma. Experimental Hematology & Oncology. 2012, 1 (1): 30-10.1186/2162-3619-1-30. ArticleCAS Google Scholar
Alduaij W, Illidge TM: The future of anti-CD20 monoclonal antibodies: are we making progress?. Blood. 2011, 117 (11): 2993-3001. 10.1182/blood-2010-07-298356. ArticleCASPubMed Google Scholar
Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA: Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011, 117 (17): 4519-4529. 10.1182/blood-2010-07-296913. ArticlePubMed CentralCASPubMed Google Scholar
Tedder TF, Engel P: CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994, 15 (9): 450-454. 10.1016/0167-5699(94)90276-3. ArticleCASPubMed Google Scholar
Goldenberg DM, Morschhauser F, Wegener WA: Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma. 2010, 51 (5): 747-755. 10.3109/10428191003672123. ArticleCASPubMed Google Scholar
Uchiyama S, Suzuki Y, Otake K, Yokoyama M, Ohta M, Aikawa S, Komatsu M, Sawada T, Kagami Y, Morishima Y: Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope. Cancer Sci. 2010, 101 (1): 201-209. 10.1111/j.1349-7006.2009.01392.x. ArticleCASPubMed Google Scholar
Robak T, Robak E: New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2011, 25 (1): 13-25. 10.2165/11539590-000000000-00000. ArticleCAS Google Scholar
Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC: The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood. 2010, 116 (19): 3705-3714. 10.1182/blood-2010-04-001230. ArticlePubMed CentralCASPubMed Google Scholar
Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, Ivanov A, Huang P, Cragg MS, Illidge TM: Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood. 2012, 119 (15): 3523-3533. 10.1182/blood-2011-12-395541. ArticleCASPubMed Google Scholar
Czuczman MS, Gregory SA: The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leukemia & lymphoma. 2010, 51 (6): 983-994. 10.3109/10428191003717746. ArticleCAS Google Scholar
Plosker GL, Figgitt DP: Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003, 63 (8): 803-843. 10.2165/00003495-200363080-00005. ArticleCASPubMed Google Scholar
Coiffier B, Pfreundschuh M, Stahel R, Vose J, Zinzani PL: Aggressive lymphoma: improving treatment outcome with rituximab. Anticancer Drugs. 2002, 13 (Suppl 2): S43-50. ArticleCASPubMed Google Scholar
Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani P: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006, 7 (5): 379-391. 10.1016/S1470-2045(06)70664-7. ArticleCASPubMed Google Scholar
Delaloye AB, Antonescu C, Louton T, Kuhlmann J, Hagenbeek A: Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial. J Nucl Med. 2009, 50 (11): 1837-1843. 10.2967/jnumed.109.067587. ArticleCASPubMed Google Scholar
Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu SS, Banay R: Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol. 2009, 20 (4): 709-714. 10.1093/annonc/mdn692. ArticleCASPubMed Google Scholar
Friedberg JW, Fisher RI: Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther. 2004, 4 (1): 18-26. 10.1586/14737140.4.1.18. ArticleCASPubMed Google Scholar
Buchegger F, Antonescu C, Helg C, Kosinski M, Prior JO, Delaloye AB, Press OW, Ketterer N: Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission. J Nucl Med. 2011, 52 (6): 896-900. 10.2967/jnumed.111.087460. ArticlePubMed Google Scholar
Corazzelli G, Frigeri F, Marcacci G, Capobianco G, Arcamone M, Becchimanzi C, Russo F, Pinto A: Rituximab plus gemcitabine, ifosfamide, oxaliplatin (R-GIFOX) as salvage therapy for recurrent Hodgkin lymphoma. ASCO Meeting Abstracts. 2009, 27 (15S): 8579- Google Scholar
El Gnaoui T, Dupuis J, Belhadj K, Rahmouni A, Copie-Bergman C, Gaillard I, Divine M, Tabah-Fisch IM, Reyes F, Haioun C: Rituximab, gemcitabine and oxaliplatin (R-GEMOX): An effective regimen for relapsed and refractory B-cell lymphoma. ASCO Meeting Abstracts. 2006, 24 (18): 7562- Google Scholar
Federico M, Luminari S, Dondi A, Sacchi S, Franco V, Pileri S, Lombardo M, Rossi G, Arcaini L, Chisesi T: R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL). ASCO Meeting Abstracts. 2012, 30 (15): 8006- Google Scholar
Recher C, Coiffier B, Haioun C, Molina TJ, Ferme C, Casasnovas O, Thieblemont C, Bosly A, Laurent G, Morschhauser F: Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011, 378 (9806): 1858-1867. 10.1016/S0140-6736(11)61040-4. ArticleCASPubMed Google Scholar
Reynolds C, Di Bella N, Lyons RM, Hyman W, Richards DA, Robbins GJ, Vellek M, Boehm KA, Zhan F, Asmar L: A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Investigational new drugs. 2012, 30 (3): 1232-1240. 10.1007/s10637-011-9737-y. ArticleCASPubMed Google Scholar
Rummel MJ, Niederle N, Maschmeyer G, Banat AG, von Gruenhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C: Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. ASCO Meeting Abstracts. 2012, 30 (18): 3- Google Scholar
Tilly H, Morschhauser F, Salles G, Casasnovas RO, Feugier P, Molina TJ, Jardin F, Terriou L, Haioun C, Coiffier B: Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia. 2012, 26:http://www.ncbi.nlm.nih.gov/pubmed/22733106, Google Scholar
Tsimberidou AM, Wierda WG, Badoux X, Wen S, Plunkett W, O'Brien SM, Kipps TJ, Jones JA, Kantarjian H, Keating MJ: Evaluation of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in aggressive chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS). ASCO Meeting Abstracts. 2010, 28 (15): 6521- Google Scholar
Tsimberidou AM, Wierda WG, Plunkett WK, O'Brien S, Lerner S, Smith SC, Kantarjian HM, Keating MJ: Phase I/II study of oxaliplatin, fludarabine, cytarabine, and rituximab in patients (OFAR2) with Richter's syndrome (RS), and relapsed or refractory B-cell chronic lymphocytic leukemia (CLL). ASCO Meeting Abstracts. 2009, 27 (15S): 7031- Google Scholar
Baig NA, Taylor RP, Lindorfer MA, Church AK, Laplant BR, Pavey ES, Nowakowski GS, Zent CS: Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. Leuk Lymphoma 2012:http://www.ncbi.nlm.nih.gov/pubmed/22475085\. 2012.
Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, Wooldridge J, Kloczko J, Holowiecki J, Hellmann A: Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1–2 study. Blood. 2008, 111 (3): 1094-1100. ArticleCASPubMed Google Scholar
Wierda WG, Kipps TJ, Durig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ: Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011, 117 (24): 6450-6458. 10.1182/blood-2010-12-323980. ArticleCASPubMed Google Scholar
Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M: Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010, 28 (10): 1749-1755. 10.1200/JCO.2009.25.3187. ArticleCASPubMed Google Scholar
Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A, Hx CDSI: Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood. 2011, 118 (19): 5126-5129. 10.1182/blood-2011-04-348656. ArticleCASPubMed Google Scholar
Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC, Gibbs JF, Deeb G, Czuczman MS: Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br J Haematol. 2012, 156 (4): 490-498. 10.1111/j.1365-2141.2011.08966.x. ArticleCASPubMed Google Scholar
Cheson BD: Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol. 2010, 28 (21): 3525-3530. 10.1200/JCO.2010.27.9836. ArticleCASPubMed Google Scholar
Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A: Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012, 119 (16): 3698-3704. 10.1182/blood-2011-09-378323. ArticleCASPubMed Google Scholar
Czuczman MS, Hess G, Gadeberg OV, Pedersen LM, Goldstein N, Gupta I, Jewell RC, Lin TS, Lisby S, Strange C: Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. Br J Haematol. 2012, 157 (4): 438-445. 10.1111/j.1365-2141.2012.09086.x. ArticleCASPubMed Google Scholar
Morschhauser F, Marlton P, Vitolo U, Linden O, Seymour JF, Crump M, Coiffier B, Foa R, Wassner E, Burger HU: Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol. 2010, 21 (9): 1870-1876. 10.1093/annonc/mdq027. ArticleCASPubMed Google Scholar
Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM: Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res. 2004, 10 (8): 2868-2878. 10.1158/1078-0432.CCR-03-0493. ArticleCASPubMed Google Scholar
Saleh MN, Liebman H, Bernstein ZP, Negrea OG, Bussel JB, Onyegbula AC, Farber CM, Abassi R, Cosgriff TM, Pennington K: Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP). ASH Annual Meeting Abstracts. 2009, 114 (22): 1322- Google Scholar
Tobinai K, Ogura M, Kobayashi Y, Uchida T, Watanabe T, Oyama T, Maruyama D, Suzuki T, Mori M, Kasai M: Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma. Cancer Sci. 2011, 102 (2): 432-438. 10.1111/j.1349-7006.2010.01809.x. ArticleCASPubMed Google Scholar
Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, Dang NH, Carpenter SP, Allan BW, Nelson JG, Slapak CA: Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012, 18 (5): 1395-1403. 10.1158/1078-0432.CCR-11-0850. ArticleCASPubMed Google Scholar
Wayne JL, Ganjoo KN, Pohlman BL, De Vos S, Flinn IW, Dang NH, Mapara MY, Smith MR, O'Reilly AM, Marulappa SY: Efficacy of ocaratuzumab (AME-133v) in relapsed follicular lymphoma patients refractory to prior rituximab. ASCO Meeting Abstracts. 2012, 30 (15): 8081- Google Scholar
Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, Bieska G, Asikanius E, Carlile D, Birkett J: Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012, 119 (22): 5126-5132. 10.1182/blood-2012-01-404368. ArticleCASPubMed Google Scholar
Carlile D, Meneses-Lorente G, Wassner-Fritsch E, Hourcade-Potelleret F, Wenger MK, Cartron G, Vitolo U, Radford J, Davies A, Morschhauser F: Pharmacokinetics of Obinutuzumab (GA101) in Patients with CD20+ Relapsed/Refractory Malignant Disease Receiving Concomitant Chemotherapy (Phase Ib Study BO21000). ASH Annual Meeting Abstracts. 2011, 118 (21): 3704- Google Scholar
Friedberg JW, Vose J, Kahl BS, Brunvand M, Goy A, Kasamon Y, Brington B, Li J, Ho W, Cheson BD: A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20+ Indolent NHL: Correlation Between Clinical Responses and AUC Pharmacokinetics. ASH Annual Meeting Abstracts. 2009, 114: 3472- Google Scholar
Kahl BS, Cheson BD, Friedberg JW: Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy. Clin Adv Hematol Oncol. 2010, 8 (5): 1-16. PubMed Google Scholar
van Meerten T, Hagenbeek A: CD20-targeted therapy: the next generation of antibodies. Seminars in hematology. 2010, 47 (2): 199-210. 10.1053/j.seminhematol.2010.01.007. ArticleCASPubMed Google Scholar
Friess T, Gerdes C, Nopora A, Patre M, Preiss S, van Puijenbroek E, Schuell C, Bauer S, Umana P, Klein C: GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Mediates Superior Efficacy in a Variety of NHL Xenograft Models in Comparison to Rituximab. ASH Annual Meeting Abstracts. 2007, 110 (11): 2338- Google Scholar
Heinrich D, Weinkauf M, Hutter G, Decheva K, Zimmermann Y, Hiddemann W, Dreyling MH: Differential Regulation Patterns of Anti-CD20 Antibodies GA101 and Rituximab in Mantle Cell Lymphoma. ASH Annual Meeting Abstracts. 2010, 116 (21): 1839- Google Scholar
Herting F, Bader S, Umana P, Klein C: Enhanced Activity of GA101, a Novel Type II, Glycoengineered CD20 Antibody, In Combination with Bendamustine or Fludarabine, and with the Bcl-2 Family Inhibitors ABT-737 or ABT-263. ASH Annual Meeting Abstracts. 2010, 116 (21): 3915- Google Scholar
Umana P, Ekkehard M, Peter B, Gabriele K, Ursula P, Suter T, Grau R, Schmidt C, Herter S, Gerdes C: GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Exhibits Superior Anti-Tumor Efficacy and Superior Tissue B Cell Depletion In Vivo. ASH Annual Meeting Abstracts. 2007, 110 (11): 2348- Google Scholar
Dalle S, Reslan L, Manquat SB, Herting F, Klein C, Umana P, Dumontet C: Compared Antitumor Activity of GA101 and Rituximab against the Human RL Follicular Lymphoma Xenografts in SCID Beige Mice. ASH Annual Meeting Abstracts. 2008, 112 (11): 1585- Google Scholar
Ysebaert L, Laprevotte E, Klein C, Laurent G, Fournie J-J, Quillet-Mary A: Clinical and Biological Characteristics Associated with In Vitro Activity of Anti-CD20 Monoclonal Antibodies, Rituximab and GA101, Against Chronic Lymphocytic Leukemia Cells. ASH Annual Meeting Abstracts. 2010, 116 (21): 2459- Google Scholar
Salles GA, Morschhauser F, Thieblemont C, Solal-Celigny P, Lamy T, Tilly H, Feugier P, Le Gouill S, Gyan E, Bouabdallah R: Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999). ASH Annual Meeting Abstracts. 2011, 118 (21): 268- Google Scholar
Meneses-Lorente G, Carlile D, Birkett J, Wenger MK, Cartron G, Morschhauser F, Salles GA: Pharmacokinetics of RO5072759 (GA101) In Patients with Relapsed/Refractory CD20+ Malignant Disease (Phase I/II Study BO20999). ASH Annual Meeting Abstracts. 2010, 116 (21): 1833- Google Scholar
Sehn LH, Goy A, Offner FC, Martinelli G, Friedberg J, Lasserre SF, Fine G, Press OW: Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study. ASH Annual Meeting Abstracts. 2011, 118 (21): 269- Google Scholar
Batty N, Malouf G, Issa J: Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett. 2009, 280: 192-200. 10.1016/j.canlet.2009.03.013. ArticleCASPubMed Google Scholar
Brown JR, Sharman JP, Harb WA, Kelly KR, Schreeder MT, Sweetenham JW, Barr PM, Foran JM, Gabrilove JL, Kipps TJ: Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL). ASCO Meeting Abstracts. 2012, 30 (15): 8032- Google Scholar
Budhu A, Ji J, Wang X: The clinical potential of microRNAs. Journal of Hematology & Oncology. 2010, 3 (1): 37-10.1186/1756-8722-3-37. ArticleCAS Google Scholar
Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Sharman JP, Flinn IW, Grant BW, Heerema NA, Johnson AJ: The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study. ASCO Meeting Abstracts. 2012, 30 (15): 6507- Google Scholar
Chanan-Khan A, Cheson B: Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol. 2008, 26: 1544-1552. 10.1200/JCO.2007.14.5367. ArticleCASPubMed Google Scholar
Chang JE, Kahl BS: Bendamustine: more ammunition in the battle against mantle cell lymphoma. Leuk Lymphoma. 2012, 53 (7): 1249-1250. 10.3109/10428194.2011.654342. ArticleCASPubMed Google Scholar
Elbaz H, Stueckle T, Tse W, Rojanasakul Y, Dinu C: Digitoxin and its analogs as novel cancer therapeutics. Experimental Hematology & Oncology. 2012, 1 (1): 4-10.1186/2162-3619-1-4. ArticleCAS Google Scholar
Ge X, Wang X: Role of Wnt canonical pathway in hematological malignancies. Journal of Hematology & Oncology. 2010, 3 (1): 33-10.1186/1756-8722-3-33. ArticleCAS Google Scholar
Johnson P: New targets for lymphoma treatment. Ann Oncol. 2008, 19 (4): 56-59. Google Scholar
Patrick J, Yuan R, Cavalli F, Thomas W: Targeted therapy of lymphoma. J Hematol Oncol. 2010, 3: 45-10.1186/1756-8722-3-45. ArticleCAS Google Scholar
Tan J, Cang S, Ma Y, Petrillo RL, Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010, 3: 5-10.1186/1756-8722-3-5. ArticlePubMed CentralPubMedCAS Google Scholar
Turkson J: STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets. 2004, 8 (5): 409-422. 10.1517/14728222.8.5.409. ArticleCASPubMed Google Scholar
Wu ZL, Song YQ, Shi YF, Zhu J: High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J Hematol Oncol. 2011, 4 (1): 31-10.1186/1756-8722-4-31. ArticleCASPubMed Google Scholar
Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR: Novel targeted therapeutics: inhibitors of MDM2. ALK and PARP. J Hematol Oncol. 2011, 4: 16-10.1186/1756-8722-4-16. ArticleCASPubMed Google Scholar
Adams J, Palombella V, Sausville E, Johnson J, Destree A, Lazarus D, Maas J, Pien C, Prakash S, Elliott P: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999, 59: 2615-2622. CASPubMed Google Scholar
Belch A, Kouroukis C, Crump M, Sehn L, Gascoyne R, Klasa R, Powers J, Wright J, Eisenhauer E: A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol. 2007, 18: 116-121. ArticleCASPubMed Google Scholar
Blum K, Johnson J, Niedzwiecki D, Canellos G, Cheson B, Bartlett N: Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma. 2007, 48: 1313-1319. 10.1080/10428190701411458. ArticleCASPubMed Google Scholar
Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S: Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol. 2011, 12 (8): 773-784. 10.1016/S1470-2045(11)70150-4. ArticleCASPubMed Google Scholar
Kahl B, Chang J, Eickhoff J, Gilbert L, Rogers E, Werndli J, Huie M, McFarland T, Volk M, Blank J: VcR-CVAD produces a high response rate in untreated mantle cell lymphoma: a phase II study from the Wisconsin Oncology Network. Blood. 2008, 112 (Suppl 1): 265- Google Scholar
Mendler J, Kelly J, Voci S, Marquis D, Rich L, Rossi R, Bernstein S, Jordan C, Liesveld J, Fisher R: Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Ann Oncol. 2008, 19: 1759-1764. 10.1093/annonc/mdn365. ArticlePubMed CentralCASPubMed Google Scholar
Mitsiades C, Mitsiades N, Hideshima T, Richardson P, Anderson K: Proteasome inhibition as a new therapeutic principle in hematological malignancies. Curr Drug Targets. 2006, 7: 1341-1347. 10.2174/138945006778559247. ArticleCASPubMed Google Scholar
Trelle S, Sezer O, Naumann R, Rummel M, Keller U, Engert A, Borchmann P: Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018). Haematologica. 2007, 92: 568-569. 10.3324/haematol.10797. ArticleCASPubMed Google Scholar
Weigert O, Weidmann E, Mueck R, Bentz M, von Schilling C, Rohrberg R, Jentsch-Ullrich K, Hiddemann W, Dreyling M: A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study. Leuk Lymphoma. 2009, 50: 716-722. 10.1080/10428190902856790. ArticleCASPubMed Google Scholar
Habermann T, Lossos I, Justice G, Vose J, Wiernik P, McBride K, Wride K, Ervin-Haynes A, Takeshita K, Pietronigro D: Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009, 145: 344-349. 10.1111/j.1365-2141.2009.07626.x. ArticleCASPubMed Google Scholar
Altman J, Platanias L: Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. Curr Opin Hematol. 2008, 15: 88-94. 10.1097/MOH.0b013e3282f3deaa. ArticleCASPubMed Google Scholar
Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A: Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009, 27: 3822-3829. 10.1200/JCO.2008.20.7977. ArticleCASPubMed Google Scholar
Johnston P, Inwards D, Colgan J, LaPlant B, Kabat B, Habermann T, Micallef I, Porrata L, Ansell S, Reeder C: A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010, 85: 320-324. PubMed CentralCASPubMed Google Scholar
Jundt F, Raetzel N, Muller C, Calkhoven C, Kley K, Mathas S, Lietz A, Leutz A, Dorken B: A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood. 2005, 106: 1801-1807. 10.1182/blood-2004-11-4513. ArticleCASPubMed Google Scholar
Teachey D, Grupp S, Brown V: Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol. 2009, 145: 569-580. 10.1111/j.1365-2141.2009.07657.x. ArticlePubMed CentralCASPubMed Google Scholar
Witzig T, Geyer S, Ghobrial I, Inwards D, Fonseca R, Kurtin P, Ansell S, Luyun R, Flynn P, Morton R: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005, 23: 5347-5356. 10.1200/JCO.2005.13.466. ArticleCASPubMed Google Scholar
Yazbeck V, Buglio D, Georgakis G, Li Y, Iwado E, Romaguera J, Kondo S, Younes A: Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol. 2008, 36: 443-450. 10.1016/j.exphem.2007.12.008. ArticleCASPubMed Google Scholar
Yee K, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M: Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006, 12: 5165-5173. 10.1158/1078-0432.CCR-06-0764. ArticleCASPubMed Google Scholar
Chen Z, Han Z: STAT3: a critical transcription activator in angiogenesis. Med Res Rev. 2008, 28 (2): 185-200. 10.1002/med.20101. ArticleCASPubMed Google Scholar
Ding B, Yu J, Yu R, Mendez L, Shaknovich R, Zhang Y, Cattoretti G, Ye B: Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood. 2008, 111 (3): 1515-1523. ArticlePubMed CentralCASPubMed Google Scholar
Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany-Amorim C: Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clin Cancer Res. 2009, 15 (12): 4038-4045. 10.1158/1078-0432.CCR-08-2808. ArticleCASPubMed Google Scholar
Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM: SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res. 2011, 17 (20): 6448-6458. 10.1158/1078-0432.CCR-11-0485. ArticleCASPubMed Google Scholar
Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S: Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma. J Clin Oncol. 2012, 30 (22): 2776-2782. 10.1200/JCO.2011.39.4403. ArticleCASPubMed Google Scholar
Coiffier B, Morschhauser F, Dupuis J, Haioun C, Laine F, Houot R, Tilly H, Brehar O, Lambert JM, Fagniez N: Phase I study cohort evaluating an optimized administration schedule of SAR3419, an anti-CD19 DM4-loaded antibody drug conjugate (ADC), in patients (pts) with CD19 positive relapsed/refractory b-cell non-Hodgkin's lymphoma (NCT00796731). ASCO Meeting Abstracts. 2012, 30 (15): 8057- Google Scholar
Schweizer A, Wohner M, Prescher H, Brossmer R, Nitschke L: Targeting of CD22-positive B-cell lymphoma cells by synthetic divalent sialic acid analogues. Eur J Immunol. 2012, 2012: 2012-http://www.ncbi.nlm.nih.gov/pubmed/22777817, Google Scholar
Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S: Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. The lancet oncology. 2012, 13 (4): 403-411. 10.1016/S1470-2045(11)70386-2. ArticleCASPubMed Google Scholar
Hoelzer D: Anti-CD22 therapy in acute lymphoblastic leukaemia. The lancet oncology. 2012, 13 (4): 329-331. 10.1016/S1470-2045(12)70010-4. ArticlePubMed Google Scholar
Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I: Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012, 30 (15): 1822-1828. 10.1200/JCO.2011.38.1756. ArticleCAS Google Scholar
Ogura M, Hatake K, Ando K, Tobinai K, Tokushige K, Ono C, Ishibashi T, Vandendries E: Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer science. 2012, 103 (5): 933-938. 10.1111/j.1349-7006.2012.02241.x. ArticleCASPubMed Google Scholar
Sharkey RM, Govindan SV, Cardillo TM, Goldenberg DM: Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Molecular cancer therapeutics. 2012, 11 (1): 224-234. 10.1158/1535-7163.MCT-11-0632. ArticleCASPubMed Google Scholar
Ma H, Qazi S, Ozer Z, Gaynon P, Reaman GH, Uckun FM: CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia. British journal of haematology. 2012, 156 (1): 89-98. 10.1111/j.1365-2141.2011.08901.x. ArticleCASPubMed Google Scholar
de Vries JF, Zwaan CM, De Bie M, Voerman JS, den Boer ML, van Dongen JJ, van der Velden VH: The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2012, 26 (2): 255-264. 10.1038/leu.2011.206. ArticleCAS Google Scholar
Chen WC, Sigal DS, Saven A, Paulson JC: Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22. Leukemia & lymphoma. 2012, 53 (2): 208-210. 10.3109/10428194.2011.604755. ArticleCAS Google Scholar
Biberacher V, Decker T, Oelsner M, Wagner M, Bogner C, Schmidt B, Kreitman RJ, Peschel C, Pastan I, Meyer Zum Buschenfelde C: The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-betaII depletion. Haematologica. 2012, 97 (5): 771-779. 10.3324/haematol.2011.049155. ArticlePubMed CentralCASPubMed Google Scholar
Sikder MA, Friedberg JW: Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma. Curr Hematol Malig Rep. 2008, 3 (4): 187-193. 10.1007/s11899-008-0027-5. ArticlePubMed Google Scholar
Gualberto A: Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. Expert Opin Investig Drugs. 2012, 21 (2): 205-216. 10.1517/13543784.2011.641532. ArticleCASPubMed Google Scholar
Nathwani N, Krishnan AY, Huang Q, Kim Y, Karanes C, Smith EP, Forman SJ, Sievers E, Thomas SH, Chen RW: Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure. Leuk Lymphoma. 2012,http://www.ncbi.nlm.nih.gov/pubmed/22369501, Google Scholar
Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, Senter PD, Alley SC: Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010, 16 (3): 888-897. 10.1158/1078-0432.CCR-09-2069. ArticleCASPubMed Google Scholar
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010, 363 (19): 1812-1821. 10.1056/NEJMoa1002965. ArticleCASPubMed Google Scholar